BMS at June 2022 oncology and hematology congresses
Driving transformative science to advance the future of cancer care for all
Intended for U.S. scientific audiences only.
Our data at the 2022 American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) Annual Meetings reinforce our commitment to transforming the lives of patients with cancer and blood disorders through science. We look forward to sharing research across immuno-oncology, hematology and cell therapy that underscores our efforts to deliver long-term survival and improved outcomes for patients, providing options earlier in the cancer treatment continuum and introducing new mechanisms and clinical approaches.
Hear from our CEO, Giovanni Caforio, MD, and others about our progress in delivering treatment advances for patients with cancer and blood disorders and how we are working to improve outcomes for all impacted by these diseases.
Read more about our key data being presented.
- Five-year survival outcomes from our first-line dual immunotherapy treatment in metastatic non-small cell lung cancer >
- Three-year results for our dual immunotherapy-based combination with chemotherapy in metastatic non-small cell lung cancer >
- First disclosure of results from primary analysis of Phase 2 study of our CAR T cell therapy in patients with primary relapsed or refractory large B-cell lymphoma >
- Preview our key data being presented >
Delivering longer-term clinical benefits
Over the past several decades, our innovative medicines have improved how cancer is treated, making longer-term survival and improved outcomes a possibility for more patients. However, our focus remains on what we have yet to accomplish.
Our Vice President and Thoracic Cancers Development Lead Abderrahim Oukessou, MD, and lung cancer expert Adam Schoenfeld, MD, Memorial Sloan Kettering Cancer Center, discuss the transforming lung cancer research landscape, including progress across different lung cancer types, stages and patient groups.
Learn from Sandra Kurtin, PhD, ANP-C, AOCN, University of Arizona Cancer Center, about ongoing research to uncover why red blood cells don’t mature properly in myelodysplastic syndromes and how targeting different stages of their maturation may lead to much-needed new therapeutic options.
Intervening earlier to change the course of disease
By researching the use of therapies earlier in the cancer treatment continuum, we aim to reduce the risk of recurrence, with the ultimate goal of helping patients live longer and with improved quality of life.
Learn from physicians, advocates and researchers, including our Vice President of Oncology Development, Mark Rutstein, MD, about the unmet medical needs in earlier-stage cancer, and the potential for immunotherapy to disrupt the course of recurrence.
Our pursuit of medical innovation
Science never stops. We are committed to making ongoing advancements in cancer research to bring patients new transformational medicines.
Cancer cells are not only stubborn, they are smart. Hear from Lata Jayaraman, head of Oncology Drug Discovery at our Mechanisms of Cancer Resistance Thematic Research Center, as she discusses the challenges of finding solutions to cancer resistance mechanisms.
Making scientific breakthroughs accessible and equitable for all
All patients deserve access to quality care and effective treatments. Through our commitment to health equity, we are working to improve outcomes across all populations impacted by cancers and blood disorders.
Learn about our dedication to addressing health disparities through our COLORS training program, designed to help oncologists understand the unique challenges and medical needs facing LGBTQ+ patients.
We take a holistic view toward narrowing the gap in outcomes for African Americans with multiple myeloma because so many factors have contributed to this issue for so long.
Our research spans several types of cancer and blood disorders. Learn about some of them below.
Exploring the tumor microenvironment to better understand how cancer and the immune system coexist is a core component of our research and early development strategy.
Discover how cell therapies are unlocking new potential in cancer research and in some of the most difficult-to-treat blood cancers.
Disease state infographics
Download infographic resources on different cancers and disease types.